News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Alan Bakst, PharmD, MBA

Articles by Alan Bakst, PharmD, MBA

Reduction in Use of Healthcare Services With Combination Sulfonylurea and Rosiglitazone: Findings From the Rosiglitazone Early vs SULfonylurea Titration (RESULT) Study

ByWilliam H. Herman, MD, MPH,Riad G. Dirani, PhD,Ruslan Horblyuk, MBA,M. Colleen O'Neill, BSc,Barbara Kravitz, MS,Mark A. Heise, PhD,Alan Bakst, PharmD, MBA,Martin I. Freed, MD,the RESULT St

April 1st 2005

Latest Updated Articles

Reduction in Use of Healthcare Services With Combination Sulfonylurea and Rosiglitazone: Findings From the Rosiglitazone Early vs SULfonylurea Titration (RESULT) Study
Published: April 1st 2005 | Updated:

Trending on AJMC

Government Shutdown Concluded but ACA Subsidies in Limbo

Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin

FDA Approves Ziftomenib for R/R NPM1-Mutated AML

Stronger Carer-Child Bonds Don’t Predict Later Mental Health

Nipocalimab Investigation Extends to Younger Patients: Jonathan Strober, MD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.